Tag Archives: Mike Rencheck

CNA2019

Innovation in action panel at CNA2019

Left to right: Jeff Lyash, Gaëtan Thomas, Mike Rencheck

On Thursday, February 28, at 2:00 p.m., Jeff Lyash, Mike Rencheck and Gaëtan Thomas will take the stage at CNA2019 to discuss new nuclear, innovation in action.

Not everyone realizes the full range of climate and health solutions offered by nuclear technology. Many of these solutions flow from the operations of nuclear utilities. Refurbishment and Major Component Replacement are sources of highly innovative advances in environmental protection, clean energy generation, and life-saving medical isotopes. New Nuclear is innovative, relevant to society’s needs, capable, job-creating, and impactful.

Jeff Lyash is President and CEO of Ontario Power Generation (OPG)  Jeff was formerly the President of CB&I Power where he was responsible for a full range of engineering, procurement and construction of multi-billion dollar electrical generation projects in both domestic and international markets. He also provided operating plant services for nuclear, coal, gas, oil and renewable generation.

Mike Rencheck is President and CEO of Bruce Power. Over the past 30+ years, Mike has served in a number of roles and most recently was the Deputy Chief Operating Officer for AREVA overseeing its extensive Global capital portfolio of nuclear and renewable projects. Prior to this, he served as President and CEO of AREVA Inc. in North America leading its diverse nuclear services business in Canada and the United States with a workforce of about 5,000 people.

Gaëtan Thomas is President and CEO of New Brunswick Power. He is a committed industry leader and agent of change, driven by his deep connection to customer and employee grassroots.

His vision for NB Power includes a made-in-New Brunswick smart grid supported by customer-centric technology and a workforce aimed at creating a greener, more sustainable province. This plan, now in its fourth year, is helping to reduce reliance on fossil fuels, lowering costs and keeping customer rates low and stable.

For more information about CNA2019 visit https://cna.ca/cna2019/.

Uncategorized

Bruce Power to produce Lutetium-177 for cancer therapy

In late June, Bruce Power joined forces with Isotopen Technologien München (ITM) to examine the production of the radioisotope Lutetium-177 at the Bruce Power site.

Lu-177 is used in targeted radionuclide therapy to treat cancers like neuroendocrine tumours and prostate cancer.

The medical-grade radioisotope is used to destroy cancer cells while leaving healthy cells unaffected.

According to the company, the Bruce Power site has the ability to meet global supply needs through 2064, which is the lifespan of the station after refurbishment.

Bruce Power nuclear generating station

“By developing innovative ways to generate these radioisotopes, we help ensure that the medical community has access to a reliable source of medical radioisotopes for Targeted Radionuclide Therapy,” Bruce Power CEO Mike Rencheck said via a press release.

Bruce’s CANDU reactors already produce Cobalt-60, which is used for the sterilization of medical equipment and in a specialized form of cancer treatment called the Gamma Knife.

Bruce Power is part of the Canadian Nuclear Isotope Council (CNIC), which aims to develop collective solutions to maintain Canada’s leadership position in global isotope production. The CNA is also a member of the Council.